stoxline Quote Chart Rank Option Currency Glossary
  
Humanigen, Inc. (HGEN)
0.0002  -0.001 (-84.62%)    01-04 13:45
Open: 0.0005
High: 0.0005
Volume: 2,063,685
  
Pre. Close: 0.0013
Low: 0.0001
Market Cap: 0(M)
Technical analysis
2024-03-22 4:48:37 PM
Short term     
Mid term     
Targets 6-month :  0 1-year :  0
Resists First :  0 Second :  0
Pivot price 0
Supports First :  0 Second :  0
MAs MA(5) :  0 MA(20) :  0
MA(100) :  0 MA(250) :  0.06
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 42.2
52-week High :  0.2 Low :  0
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HGEN ] has closed above bottom band by 37.5%. Bollinger Bands are 93.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 138 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0 - 0 0 - 0
Low: 0 - 0 0 - 0
Close: 0 - 0 0 - 0
Company Description

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ‘cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Headline News

Fri, 03 May 2024
Humanigen, Inc. (NASDAQ:HGEN) On The Verge Of Breaking Even - Yahoo Movies Canada

Thu, 02 May 2024
Do Options Traders Know Something About Humanigen (HGEN) Stock We Don't? - Yahoo Movies UK

Fri, 05 Jan 2024
Humanigen Downfall: FDA Rejection For COVID-19 Drug Triggers Financial Crisis, Bankruptcy - Humanigen Inc - Benzinga

Fri, 05 Jan 2024
HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy - InvestorPlace

Thu, 04 Jan 2024
Humanigen stock falls on bankruptcy filing (OTCMKTS:HGEN) - Seeking Alpha

Tue, 25 Jul 2023
Humanigen stock falls on bankruptcy plan and delisting - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 119 (M)
Held by Insiders 1.1048e+008 (%)
Held by Institutions 10.3 (%)
Shares Short 3,320 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 916.2 %
Return on Equity (ttm) -85.1 %
Qtrly Rev. Growth 1.7e+006 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -64 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 4.14e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android